March 5, 2026
BURLINGTON, Ontario — March 5, 2026 — Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF), a Canadian biotechnology company specializing in oral thin film drug delivery technology, today announced the grant of a key patent for its QuickStrip™ Nicotine Bilayer Oral Film in partnership with...
February 23, 2026
BURLINGTON, Ontario – February 23, 2026 – Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF), (“RDT” or the “Company”), a Canadian biotechnology company focused on innovative drug delivery solutions, today provided an update on its ongoing cannabinoid research initiatives and clinical evaluation of its proprietary...
February 11, 2026
Burlington, Ontario – February 11, 2026 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE; OTCQB: RDTCF), a Canadian biotechnology company revolutionizing drug delivery through innovation, today announced that its common shares are now trading in the United States on the OTCQB Venture...
February 10, 2026
Burlington, Ontario – February 9, 2026 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE|OTCQB: RDTCF), a Canadian biotechnology company focused on innovative drug delivery solutions, today announced the commercial launch of its Entourage Phytolab co-branded QuickStrip™ medical cannabis oral thin film in...
January 5, 2026
BURLINGTON, Ontario – January 5, 2026 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announced today that pursuant to the terms of its amended and restated secured convertible notes dated December 1, 2025 (the “Notes”), the Company intends to issue common shares...
December 8, 2025
BURLINGTON, Ontario – December 5, 2025 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announced today that it has extended the maturity date of its outstanding secured convertible notes (the “Notes”) previously issued on its private placement financing (the “Financing”) which closed...
November 28, 2025
BURLINGTON, Ontario – November 28, 2025 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announced today that it intends to extend the maturity date of its outstanding secured convertible notes (the “Notes”) previously issued on its private placement financing (the “Financing”) which...
November 18, 2025
In a recent interview with CEO.ca, Mark Upsdell, CEO of Rapid Dose Therapeutics (CSE: DOSE), discusses NicStrip™, the company’s nicotine oral thin film strip, as well as recent development activity, regulatory submissions in progress, and the QuickStrip ™ platform. The interview also includes information on:...
October 20, 2025
Seven-month extension valued at up to approximately $1.8 million CAD supports further evaluation as RDT advances broader commercialization initiatives for NicStrip™ Burlington, Ontario – October 20, 2025 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian life sciences company developing innovative...
October 2, 2025
BURLINGTON, Ontario – October 1, 2025 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announced today that as contemplated in the secured convertible notes (the “Notes”) previously issued on its private placement financing (the “Financing”), and consistent with prior quarters, the Company...